MC2 Therapeutics
10
1
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
10.0%
1 terminated/withdrawn out of 10 trials
88.9%
+2.4% vs industry average
30%
3 trials in Phase 3/4
113%
9 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
Role: collaborator
Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)
Role: lead
The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
Role: lead
A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
Role: lead
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects
Role: lead
This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream
Role: lead
Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream
Role: lead
Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream
Role: lead
Evaluation of the Vasoconstriction Properties of MC2-01 Cream
Role: lead
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream
Role: lead
All 10 trials loaded